These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38977180)

  • 21. Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients.
    Reckers-Droog V; van Exel J; Brouwer W
    Value Health; 2021 Aug; 24(8):1182-1192. PubMed ID: 34372984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Provision or good genes? Menstrual cycle shifts in women's preferences for short-term and long-term mates' altruistic behavior.
    Oda R; Okuda A; Takeda M; Hiraishi K
    Evol Psychol; 2014 Oct; 12(5):888-900. PubMed ID: 25340679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methods to Adjust Willingness-to-Pay Measures for Severity of Illness.
    Phelps CE; Lakdawalla DN
    Value Health; 2023 Jul; 26(7):1003-1010. PubMed ID: 36796478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altruistic Preferences in Time Tradeoff: Consideration of Effects on Others in Health State Valuations.
    Krol M; Attema AE; van Exel J; Brouwer W
    Med Decis Making; 2016 Feb; 36(2):187-98. PubMed ID: 26552410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs.
    Chambers JD; Silver MC; Berklein FC; Cohen JT; Neumann PJ
    J Gen Intern Med; 2020 Sep; 35(9):2629-2636. PubMed ID: 32291711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the value of treating schizophrenia?
    Carr VJ; Lewin TJ; Neil AL
    Aust N Z J Psychiatry; 2006; 40(11-12):963-71. PubMed ID: 17054564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altruism and anonymity: A behavioral analysis.
    Locey ML; Rachlin H
    Behav Processes; 2015 Sep; 118():71-5. PubMed ID: 26051191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incentives for orphan drug research and development in the United States.
    Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
    Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altruism, altruistic punishment and social investment.
    Jaffe K
    Acta Biotheor; 2004; 52(3):155-72. PubMed ID: 15456982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neural and cognitive characteristics of extraordinary altruists.
    Marsh AA; Stoycos SA; Brethel-Haurwitz KM; Robinson P; VanMeter JW; Cardinale EM
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15036-41. PubMed ID: 25225374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67.
    Desser AS; Gyrd-Hansen D; Olsen JA; Grepperud S; Kristiansen IS
    BMJ; 2010 Sep; 341():c4715. PubMed ID: 20861122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Would Altruistic Consumers Place A Higher Value on Sustainable Foods?
    Li H; Lin W
    Foods; 2023 Oct; 12(19):. PubMed ID: 37835353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
    Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
    Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altruism and economic behavior: II--private charity and public policy.
    Kennett DA
    Am J Econ Sociol; 1980 Oct; 39(4):337-53. PubMed ID: 10248809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An ethical appraisal of living-anonymous kidney donation using Adam Smith's Theory of Moral Sentiments.
    Khetpal V; Mossialos E
    Health Policy; 2018 Nov; 122(11):1212-1221. PubMed ID: 30190087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On aggregating QALYs: a comment on Dolan.
    Johannesson M
    J Health Econ; 1999 Jun; 18(3):381-6. PubMed ID: 10537901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Egalitarianism and altruism in health: some evidence of their relationship.
    Abásolo I; Tsuchiya A
    Int J Equity Health; 2014 Feb; 13():13. PubMed ID: 24502318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insurance companies' perspectives on the orphan drug pipeline.
    Handfield R; Feldstein J
    Am Health Drug Benefits; 2013 Nov; 6(9):589-98. PubMed ID: 24991385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.